William Ringo - Sangamo Therapeutics Independent Chairman of the Board
| SGMO Stock | USD 0.52 0.02 3.70% |
Chairman
Mr. William R. Ringo, Jr., is no longer Independent Director of the Company effective January 1, 2018. Mr. Ringo was Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. and was responsible for guiding Pfizers overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which acquired Abgenix in 2006. Mr. Ringo began his career at Eli Lilly Company in 1973 and during his 28year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. From 2001 to 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the nonexecutive chairman of the board of directors after serving as interim Chief Executive Officer from June to September 2003. Mr. Ringo served on the board of directors of Onyx Pharmaceuticals, Inc. from 2011 to 2013. Mr. Ringo also served on the board of directors of Mirati Therapeutics from 2014 to 2016 since 2016.
| Age | 70 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 501 Canal Blvd, Richmond, CA, United States, 94804 |
| Phone | 510-970-6000 |
| Web | https://www.sangamo.com |
Sangamo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.176) % which means that it has lost $0.176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3647) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to -1.48. In addition to that, Return On Capital Employed is likely to grow to -0.92. At this time, Sangamo Therapeutics' Asset Turnover is very stable compared to the past year.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Luis Orozco | Betterware De Mexico | 71 | |
| Daniel Herndon | Home Federal Bancorp | 77 | |
Management Performance
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 |
Sangamo Therapeutics Leadership Team
Elected by the shareholders, the Sangamo Therapeutics' board of directors comprises two types of representatives: Sangamo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sangamo. The board's role is to monitor Sangamo Therapeutics' management team and ensure that shareholders' interests are well served. Sangamo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sangamo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ward Wolff, CFO and Executive VP | ||
| Mark McClung, Ex COO | ||
| Stephanie CLP, Head Management | ||
| Geoffrey Nichol, Executive Vice President - Research and Development | ||
| Prathyusha Durabaibu, Principal Accounting Officer | ||
| Whitney Jones, VP Officer | ||
| Stephen Dilly, Independent Director | ||
| Stephane Boissel, Interim CFO | ||
| John Larson, Independent Director | ||
| Edward Conner, Senior Vice President and Chief Medical Officer | ||
| ChB MB, Pres CEO | ||
| Robert Carey, Independent Director | ||
| McDavid Stilwell, IR Contact Officer | ||
| Heather Erickson, Chief Staff | ||
| Elizabeth Wolffe, IR Contact Officer, Corporate Communications | ||
| Karen Smith, Director | ||
| Nathalie DuboisStringfellow, Senior Officer | ||
| Louise Wilkie, Vice Communications | ||
| Michael Holmes, Senior Vice President CTO | ||
| Stewart Parker, Director | ||
| Jason Fontenot, Senior Vice President Cell Therapy | ||
| Phillip Ramsey, Head Operations | ||
| David Ojala, Scientist Research | ||
| Adrian Woolfson, Executive Vice President of Research and Development | ||
| Alexander Macrae, President CEO, Director | ||
| Andrew Ramelmeier, Ex Operations | ||
| Scott Willoughby, General VP | ||
| Steven Mento, Independent Director | ||
| Heather Turner, Senior Vice President General Counsel | ||
| Gregory Davis, Head Technology | ||
| Curt Herberts, Senior Vice President and Chief Business Officer | ||
| Lisa MD, Chief Officer | ||
| Aron Feingold, Head Officer | ||
| Amy Pooler, Head Research | ||
| Saira Ramasastry, Independent Director | ||
| Edward Lanphier, President CEO, Director | ||
| Roger Jeffs, Director | ||
| Kathy Yi, CFO, Senior Vice President | ||
| William Ringo, Independent Chairman of the Board | ||
| Paul Cleveland, Independent Director | ||
| Edward Rebar, Senior Vice President CTO | ||
| Joseph Zakrzewski, Director | ||
| Dale Ando, Vice President - Therapeutic Development, Chief Medical Officer |
Sangamo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sangamo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (24.76) % | ||||
| Current Valuation | 56.41 M | ||||
| Shares Outstanding | 203.67 M | ||||
| Shares Owned By Insiders | 9.40 % | ||||
| Shares Owned By Institutions | 49.90 % | ||||
| Number Of Shares Shorted | 11.41 M | ||||
| Price To Earning | (15.31) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sangamo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sangamo Therapeutics' short interest history, or implied volatility extrapolated from Sangamo Therapeutics options trading.
Currently Active Assets on Macroaxis
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.